SCHEMBL2011634

SCHEMBL2011634

CN(C)C(=O)c1cnccn1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
NAPRT Q6XQN6 1/20 0.57
HCAR2 Q8TDS4 1/20 0.57
TSHR P16473 2/20 0.55
ADORA3 P0DMS8 1/20 0.55
MC4R P32245 1/20 0.55
ADRA1A P35348 1/20 0.55
MC3R P41968 1/20 0.55
HSD17B10 Q99714 1/20 0.47
BAZ2B Q9UIF8 1/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.42
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31086815 1.00 KDM4E (0.57) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL3461908 0.84 TSHR (0.57) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL2568939 0.81 KDM4E (0.50) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL2311114 0.81 KDM4E (0.50) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL16011500 0.81 KDM4E (0.59) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL28269739 0.80 KDM4E (0.53) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL28851350 0.79 TSHR (0.61) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL28154213 0.79 KDM4E (0.57) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL2570916 0.79 ALDH1A1 (0.54) KDM4ENAPRTHCAR2TSHRADORA3
SCHEMBL28059982 0.79 KDM4E (0.52) KDM4ENAPRTHCAR2TSHRADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023213308-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 苏州隆博泰药业有限公司 2023-11-09 WO claimed
CN-106573914-B Pyrazolyl-ureas as kinase inhibitors 瑞斯比维特有限公司 2021-05-28 CN claimed
CN-108349944-B Indolin-2-one derivatives 豪夫迈·罗氏有限公司 2021-03-30 CN claimed
CN-106103421-B The pyrazine regulator of GPR6 武田药品工业株式会社 2019-04-09 CN claimed
CN-108349944-A INDOLIN-2-ONE DERIVATIVES 豪夫迈·罗氏有限公司 2018-07-31 CN claimed
CN-106573914-A Pyrazolyl-ureas as kinase inhibitors 瑞斯比维特有限公司 2017-04-19 CN claimed
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 US disclosed
US-12441689-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2025-10-14 US disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 US disclosed
US-20240425513-A1 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 CARMOT THERAPEUTICS, INC. 2024-12-26 US disclosed
CN-118103364-A Pyrazinyl-triazole compounds as pesticides 拜耳公司 2024-05-28 CN disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 CN disclosed
US-5461167-A 2-chloro-5-chloromethyl thiazole; insecticide NIHON BAYER AGROCHEM K.K. (JP) 1995-10-24 US disclosed
US-5428032-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1995-06-27 US disclosed
US-5298507-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1994-03-29 US disclosed
US-5204360-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1993-04-20 US disclosed
US-5001138-A Insecticides NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) 1991-03-19 US disclosed
US-4845106-A INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1989-07-04 US disclosed
US-4742060-A 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) 1988-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 KDM4E 858/4885NAPRT 3106/4885HCAR2 4848/4885
US-20240425513-A1 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 USP28, USP25, USP39 KDM4E 1197/4885NAPRT 2553/4885HCAR2 3410/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 KDM4E 858/4885NAPRT 3106/4885HCAR2 4848/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 KDM4E 1262/4885NAPRT 3025/4885HCAR2 1157/4885
US-12441689-B2 ACSS2 inhibitors and methods of use thereof ACSS2, ADSS2, GLS2 KDM4E 1691/4885NAPRT 1637/4885HCAR2 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.